EMERGENT BIOSOLUTIONS INC (EBS) 13.1 -0.37 (-2.75%)
13.1 -0.37 (-2.75%)
US29089Q1058 - Common Stock
Buy % Consensus
Analysts have set a mean price target of 31.11. This target is 137.48% above the current price.
EBS was analyzed by 11 analysts. The buy percentage consensus is at 71. So analysts seem to be have mildly positive about EBS.
In the previous month the buy percentage consensus was at a similar level.
EBS was analyzed by 11 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target
Up and Down Grades
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2022-11-10 | Benchmark | Downgrade | Buy -> Hold |
| 2022-11-09 | Chardan Capital | Maintains | Buy |
| 2022-09-12 | Cowen & Co. | Maintains | Market Perform |
| 2022-05-04 | Wells Fargo | Maintains | Equal-Weight |
| 2022-04-29 | Chardan Capital | Maintains | Buy |
| 2022-03-10 | Wells Fargo | Maintains | Equal-Weight |
| 2021-11-10 | Chardan Capital | Maintains | Buy |
| 2021-11-08 | Benchmark | Downgrade | Buy -> Hold |
| 2021-05-05 | Argus Research | Downgrade | Buy -> Hold |
| 2021-04-30 | Chardan Capital | Maintains | Buy |
| 2021-04-07 | Benchmark | Initiate | Buy |
| 2021-02-24 | Chardan Capital | Upgrade | Neutral -> Buy |
| 2021-02-19 | Chardan Capital | Downgrade | Buy -> Neutral |
Analyst Ratings Stock Screener Links
Best Analyst Rating Competitors Stock Screener
Find the competitors with the best analyst ratings on the USA